Advisory Alpha LLC Raises Stock Position in Abbott Laboratories (NYSE:ABT)

Advisory Alpha LLC grew its holdings in shares of Abbott Laboratories (NYSE:ABTGet Rating) by 23.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,207 shares of the healthcare product maker’s stock after purchasing an additional 1,005 shares during the period. Advisory Alpha LLC’s holdings in Abbott Laboratories were worth $733,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ABT. Bedel Financial Consulting Inc. lifted its stake in Abbott Laboratories by 3.2% in the fourth quarter. Bedel Financial Consulting Inc. now owns 2,496 shares of the healthcare product maker’s stock valued at $351,000 after buying an additional 77 shares in the last quarter. Webster Bank N. A. grew its stake in shares of Abbott Laboratories by 0.8% during the fourth quarter. Webster Bank N. A. now owns 10,473 shares of the healthcare product maker’s stock worth $1,474,000 after buying an additional 78 shares during the last quarter. Meitav Dash Investments Ltd. grew its stake in shares of Abbott Laboratories by 0.8% during the third quarter. Meitav Dash Investments Ltd. now owns 10,250 shares of the healthcare product maker’s stock worth $1,218,000 after buying an additional 80 shares during the last quarter. Sequent Asset Management LLC grew its stake in shares of Abbott Laboratories by 1.3% in the fourth quarter. Sequent Asset Management LLC now owns 6,086 shares of the healthcare product maker’s stock worth $856,000 after purchasing an additional 80 shares during the last quarter. Finally, Centaurus Financial Inc. boosted its position in Abbott Laboratories by 1.2% during the fourth quarter. Centaurus Financial Inc. now owns 6,878 shares of the healthcare product maker’s stock valued at $968,000 after acquiring an additional 80 shares during the last quarter. Hedge funds and other institutional investors own 73.01% of the company’s stock.

In other news, SVP Michael D. Dale sold 4,000 shares of the stock in a transaction dated Tuesday, March 8th. The shares were sold at an average price of $117.00, for a total value of $468,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Andrea F. Wainer sold 456 shares of the firm’s stock in a transaction dated Tuesday, March 1st. The stock was sold at an average price of $118.13, for a total transaction of $53,867.28. The disclosure for this sale can be found here. Insiders have sold 7,896 shares of company stock worth $926,454 over the last three months. 0.52% of the stock is currently owned by insiders.

Shares of NYSE ABT traded down $1.19 during mid-day trading on Monday, reaching $116.50. The company had a trading volume of 135,063 shares, compared to its average volume of 6,072,364. The business’s 50-day moving average is $120.21 and its 200-day moving average is $125.54. The company has a current ratio of 1.85, a quick ratio of 1.46 and a debt-to-equity ratio of 0.48. The stock has a market cap of $205.45 billion, a price-to-earnings ratio of 29.58, a price-to-earnings-growth ratio of 3.17 and a beta of 0.74. Abbott Laboratories has a 52 week low of $105.36 and a 52 week high of $142.60.

Abbott Laboratories (NYSE:ABTGet Rating) last posted its quarterly earnings results on Wednesday, January 26th. The healthcare product maker reported $1.32 EPS for the quarter, topping the Zacks’ consensus estimate of $1.18 by $0.14. Abbott Laboratories had a net margin of 16.42% and a return on equity of 27.06%. The firm had revenue of $11.47 billion for the quarter, compared to analysts’ expectations of $10.71 billion. During the same period in the prior year, the business posted $1.45 earnings per share. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. As a group, equities research analysts forecast that Abbott Laboratories will post 4.78 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, May 16th. Stockholders of record on Friday, April 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 1.61%. The ex-dividend date is Wednesday, April 13th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 47.72%.

A number of brokerages have issued reports on ABT. StockNews.com initiated coverage on shares of Abbott Laboratories in a research report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Credit Suisse Group raised their price objective on shares of Abbott Laboratories from $138.00 to $139.00 and gave the company an “outperform” rating in a research report on Thursday, January 27th. Bank of America began coverage on shares of Abbott Laboratories in a research report on Tuesday, March 1st. They issued a “buy” rating and a $140.00 target price on the stock. BTIG Research cut their price target on shares of Abbott Laboratories from $143.00 to $138.00 in a report on Wednesday, January 26th. Finally, Cowen raised their price target on shares of Abbott Laboratories from $140.00 to $150.00 in a report on Monday, January 10th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $139.52.

Abbott Laboratories Profile (Get Rating)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Further Reading

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.